Corient Private Wealth’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Corient Private Wealth’s Portfolio NYMX Stock Details NYMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-25,000	Closed	-$4.75K	–	2273
2023 Q2	$4.75K	Hold	25,000	–	–	﹤0.01%	2068
2023 Q1	$8.5K	Hold	25,000	–	–	﹤0.01%	1993
2022 Q4	$7.42K	Buy	+25,000	New	+$9.05K	﹤0.01%	1683

Other funds holding NYMX

DDC

DF Dent & Co Baltimore, Maryland $5.22B AUM 2.07% 1-Year Est. Return

FCFC

First Citizens Financial Corp Mason City, Iowa $239M AUM 26.56% 1-Year Est. Return

CAM

Cubic Asset Management Boston, Massachusetts $422M AUM 29.18% 1-Year Est. Return

ODIJL

One Day In July LLC Burlington, Vermont $1.25B AUM 12.08% 1-Year Est. Return

Corient Private Wealth's NYMX Position: Q3 2023 in Review

Corient Private Wealth sold out of Nymox Pharmaceutical Corp (NYMX) in Q3 2023, closing a stake of 25,000 shares — an estimated $4.75K sold.

Corient Private Wealth first reported a position in NYMX in Q4 2022 and held it in 3 quarters. The position peaked at $8.5K in Q1 2023. 5 funds tracked by Wall St. Rank hold NYMX as of Q3 2023.

Corient Private Wealth reported no remaining Nymox Pharmaceutical Corp position as of Q3 2023 after selling out during the quarter.
Corient Private Wealth sold 25,000 Nymox Pharmaceutical Corp shares in Q3 2023, an estimated $4.75K.
Corient Private Wealth first reported a position in Nymox Pharmaceutical Corp in Q4 2022 and held it in 3 quarters.
Corient Private Wealth's Nymox Pharmaceutical Corp position peaked at $8.5K in Q1 2023.
5 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q3 2023.

Based on Corient Private Wealth's 13F filing for Q3 2023, filed 3 Nov 2023.